---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000233"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:07:04.514045+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics amends bylaws for universal proxy and Delaware law updates

## Summary
- Board approved amended restated bylaws effective November 12, 2024.
- Updates advance notice procedures for director nominations and stockholder proposals.
- Requires stockholder to show Rule 14a-19 compliance 5 business days before meeting.
- Conforms provisions to current Delaware General Corporation Law.
- Updates provisions on directors, board committees, officers, and ministerial changes.

## SEC filing metadata
- accession: 0001714899-24-000233
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/0001714899-24-000233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000233/dnli-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000233
- JSON: https://secwatch.observer/filing/0001714899-24-000233.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.